 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12345678» |
- | moxidectin / Generic mfg.
Journal: Exposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation. (Pubmed Central) - Nov 28, 2024
Bacterial anthelminthic challenging resulted in decreased anthelminthic sensitivity, and to some extent, decreased antibiotic sensitivity. Hence, potential off-target effects of large-scale administration of ivermectin and moxidectin should be carefully monitored.
- | moxidectin / Generic mfg.
Journal: Efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel for the treatment of generalised demodicosis in dogs. (Pubmed Central) - Oct 29, 2024
Hence, potential off-target effects of large-scale administration of ivermectin and moxidectin should be carefully monitored. Monthly administration of SMP was effective for the treatment of generalised demodicosis in dogs as it eliminated Demodex mites after two monthly treatments in the laboratory study, and at most after three monthly treatments in the field study.
- | moxidectin / Generic mfg.
Enrollment closed: Efficacy and Safety Study of Moxidectin in Adults with Scabies (clinicaltrials.gov) - Oct 29, 2024
P2, N=200, Active, not recruiting, Sponsor: Medicines Development for Global Health
Monthly administration of SMP was effective for the treatment of generalised demodicosis in dogs as it eliminated Demodex mites after two monthly treatments in the laboratory study, and at most after three monthly treatments in the field study. Recruiting --> Active, not recruiting
- emodepside (BAY 44-4400) / Bayer, flubentylosin (ABBV-4083) / AbbVie
Development of alternative treatments for filarial diseases (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 26, 2024 - Abstract #ASTMH2024ASTMH_4045;
The Drugs for Neglected Diseases initiative (DNDi) is investigating emodepside (with Bayer AG) and ABBV-4083 (with the Anti-Wolbachia (AWOL) consortium and AbbVie), along with multiple partners...Recent studies show its strong activity against Trichuris trichiura and hookworm infections in humans. Here, we present emodepside results for Onchocerca volvulus , recent failures, and considerations for patient access to new medicines.
- moxidectin / Generic mfg., albendazole / Generic mfg.
Safety of novel combination treatments for onchocerciasis (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 26, 2024 - Abstract #ASTMH2024ASTMH_4038;
In a new randomized, blinded trial we compare the safety and efficacy of standard doses of IA with IDA, moxidectin (mox)A and moxDA...From this ongoing study it can be concluded that after pre-treatment with ivermectin a single course of IDA, moxA or moxDA are as safe as the standard treatment for onchocerciasis in areas co-endemic for lymphatic filariasis IA. It is planned to assess the macrofilaricidal efficacy after two treatment courses 6 months apart.
- moxidectin / Generic mfg., ivermectin oral / Generic mfg.
Reduction in the prevalence of Onchocerca volvulus infection in Ituri province, Democratic Republic of Congo between 2009-2011 and 2020-2023: Results of screening for two studies comparing the efficacy and safety of moxidectin and ivermectin (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 26, 2024 - Abstract #ASTMH2024ASTMH_3915;
In 2021-2023, SmfL was 0 in 88.2% (2641/2994) and 91.4% (2323/2541) of men and women ?20 years and 96.6% (1601/1658) and 97.8% (1408/1439) of men and women 12-19 years old. Since CDTi was never implemented in the area, other factors impacting transmission, notably vector biting rates, should be investigated to understand the drivers of reduction in infection prevalence.
- moxidectin / Generic mfg., ivermectin oral / Generic mfg.
Evaluation of the Biological Activity of Chemical Constituents from the Stembark of Kigelia africana, a Cameroonian Medicinal Plant, Against Onchocerca ochengi Parasites (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 26, 2024 - Abstract #ASTMH2024ASTMH_3581;
In recent years, moxidectin has been approved for the treatment of onchocerciasis...All the tested fractions and pure compounds showed varying degrees of toxicity on the monkey epithelial cells which served as hosts for the filarial parasites. These findings open new avenues on research and development of new therapeutic agents for the treatment of onchocerciasis.
- | moxidectin / Generic mfg.
Journal: Treatment of Sarcoptic Mange in Wombats With Topical Moxidectin. (Pubmed Central) - Oct 22, 2024
Here, we presented two clinical scenarios of sarcoptic mange in wombats that were successfully treated with three 100-mL doses of moxidectin applied topically. We recommend this treatment be used where wombats can be identified and monitored throughout their recovery.
- moxidectin / Generic mfg.
Onchocerciasis Seroprevalence In Bi (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_3087;
In Bie?, prior to the initiation of MDA, we conducted a cross-sectional survey across three areas to determine suitability for a planned cluster-randomised trial of moxidectin versus ivermectin MDA...The breeding site assessments confirmed the presence of blackfly larvae in all three study areas. Our findings confirm the urgent need for MDA against onchocerciasis in this province.
- moxidectin / Generic mfg.
Safety and efficacy of a single dose of 2 mg moxidectin in Loa loa infected individuals: a double-blind, randomized ivermectin-controlled trial with ascending microfilarial densities (Convention Center - Room 345 (3rd Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_2527;
A single 2 mg MOX dose is as safe as 150 ?g/kg IVM in patients with low L loa MFD. Further studies with higher moxidectin doses and in patients with higher MFD are warranted.
- moxidectin / Generic mfg., ivermectin oral / Generic mfg.
WITHDRAWN A randomized double-blind study comparing the effect of 3 annual or five 6-monthly single doses of moxidectin or ivermectin in individuals ?12 years old with Onchocerca volvulus infection in Ituri province, Democratic Republic of . (Convention Center - Room 345 (3rd Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_2524;
The severity of 96% of AEs was mild or moderate. Details of the study design, including the cost- and time-effective nested recruitment and screening strategy with a concurrent single dose safety study, participant population and results of the 12-month efficacy and safety analyses will be presented.
- moxidectin / Generic mfg., albendazole / Generic mfg.
Moxidectin plus albendazole for lymphatic filariasis: effects through 36 months post-treatment (Convention Center - Room 343/344 (3rd Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1772;
Complete results adjusted for baseline characteristics and infection intensity for all participants will be presented at the meeting. Results from this trial suggest that mass drug administration with MoxA could accelerate LF and onchocerciasis elimination in Africa.
- moxidectin / Generic mfg.
Safety of a single dose of moxidectin and of ivermectin: first results of a large study in individuals living in an onchocerciasis endemic area of the Democratic Republic of Congo and in an onchocerciasis-lymphatic filariasis co-endemic area in . (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1579;
Results from this trial suggest that mass drug administration with MoxA could accelerate LF and onchocerciasis elimination in Africa. A double-blind study is comparing the safety of a MOX and a 150 ?g/kg IVM dose (MOX:IVM randomization ratio 4:1) in two locations: in onchocerciasis endemic areas in Ituri province of the Democratic Republic of Congo (DRC) and the onchocerciasis
- | moxidectin / Generic mfg., albendazole / Generic mfg.
Trial completion: Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole (clinicaltrials.gov) - Oct 9, 2024
P3, N=12997, Completed, Sponsor: Medicines Development for Global Health
A double-blind study is comparing the safety of a MOX and a 150 ?g/kg IVM dose (MOX:IVM randomization ratio 4:1) in two locations: in onchocerciasis endemic areas in Ituri province of the Democratic Republic of Congo (DRC) and the onchocerciasis Active, not recruiting --> Completed
- | moxidectin / Generic mfg.
Journal: Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. (Pubmed Central) - Oct 7, 2024
Moreover, some diamine and aminoalcohol derivatives showed superior efficacy inhibiting S. ratti motility compared to ivermectin, with five compounds (AA23, AA34, AO2 AO7 and AO14b) also displaying selectivity indexes on HepG2 and Caco2 higher than 1. These findings underscore the potential of these derivatives as promising alternatives for strongyloidiasis treatment, warranting further investigation and in vivo efficacy assessment.
- | moxidectin / Generic mfg.
Journal: Identification and management of infections caused by Giardia sp., Trichuris sp. and Demodex sp. in captive Brazilian porcupines (Coendou prehensilis). (Pubmed Central) - Oct 1, 2024
These findings underscore the potential of these derivatives as promising alternatives for strongyloidiasis treatment, warranting further investigation and in vivo efficacy assessment. The animals were initially treated with moxidectin (0.4 and 0.8
- | Journal: A comparative field efficacy trial of three treatment programs against endo- and ectoparasites in naturally infected dogs. (Pubmed Central) - Sep 21, 2024
The animals were initially treated with moxidectin (0.4 and 0.8 Treatments administered included oral oxibendazole/praziquantel (Paragard
- moxidectin / Generic mfg.
When more is needed: moxidectin a new tool to complement ivermectin (Convention Center - Room 357 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_589;
- moxidectin / Generic mfg., albendazole / Generic mfg., praziquantel / Generic mfg.
113 - Innovative Tools for the Control of NTDs. How to Achieve Impact through Access Beyond Drug Donations (Convention Center - Room 357 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_588;
Special attention to these innovations in pediatric populations and in the opportunities for changes in the expectations for disease control and elimination will also be discussed. The session will include a donor panel to discuss the potential, opportunities and barriers to the introduction and scale up of these and other new tools.
- moxidectin / Generic mfg., ivermectin oral / Generic mfg.
Evaluation of the Biological Activity of Chemical Constituents from the Stembark of Kigelia africana, a Cameroonian Medicinal Plant, Against Onchocerca ochengi Parasites (Convention Center - Room 356 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_109;
In recent years, moxidectin has been approved for the treatment of onchocerciasis...All the tested fractions and pure compounds showed varying degrees of toxicity on the monkey epithelial cells which served as hosts for the filarial parasites. These findings open new avenues on research and development of new therapeutic agents for the treatment of onchocerciasis.
- | moxidectin / Generic mfg.
Journal: Delayed canine heartworm (Dirofilaria immitis) microfilarial reduction following AdvocateTM for Dogs (imidacloprid, moxidectin) treatment. (Pubmed Central) - Sep 5, 2024
These findings open new avenues on research and development of new therapeutic agents for the treatment of onchocerciasis. To streamline testing of D. immitis SNPs, we developed a rhAmp
- | moxidectin / Generic mfg.
Journal: The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation. (Pubmed Central) - Aug 15, 2024
As early as two days after dosing, concentrations of moxidectin in breast milk were below the threshold for acceptable daily intake levels established by the European Medicines Agency (EMA) and FDA for secondary exposures from veterinary use, and below the WHO recommended relative infant dose (RID) safety threshold. The analyses were conducted to support prescribers and policy makers on dosing recommendations for moxidectin in lactation.
- || moxidectin / Generic mfg., levamisole / Generic mfg.
Review, Journal: Anthelmintic resistance of gastrointestinal nematodes in cattle in Brazil and Argentina - current status and global perspectives. (Pubmed Central) - Aug 14, 2024
The review explores the impact ofclimate, mixed grazing, animal movement and other husbandry practices, and the relationship between ectoparasite control and the emergence of resistant helminths. Notably, the discussion includes the strategic use of drug combinations as a valuable approach to address resistant GINs control in livestock, highlighting its significant potential to mitigate the challenges posed by AHR in the cattle industry of these countries.
- | moxidectin / Generic mfg., albendazole / Generic mfg.
Trial completion, Head-to-Head: Moxiped: Efficacy and Safety of MOX/ALB Co-administration in SAC (clinicaltrials.gov) - Aug 13, 2024
P3, N=224, Completed, Sponsor: Jennifer Keiser
Notably, the discussion includes the strategic use of drug combinations as a valuable approach to address resistant GINs control in livestock, highlighting its significant potential to mitigate the challenges posed by AHR in the cattle industry of these countries. Active, not recruiting --> Completed
- | monepantel (PAA1) / Pharmaust
Journal: Faecal egg count reduction tests and nemabiome analysis reveal high frequency of multi-resistant parasites on sheep farms in north-east Germany involving multiple strongyle parasite species. (Pubmed Central) - Aug 8, 2024
Here, the faecal egg count reduction test (FECRT) was performed on eight farms using fenbendazole, ivermectin and moxidectin and on four farms using only moxidectin...Nematode species composition in pre- and post-treatment samples was analysed with the nemabiome approach...Resistance against both drug classes on the same farm was common. Further studies including additional drugs (levamisole, monepantel, closantel) should combine sensitive FECRTs with nemabiome data to comprehensively characterise the anthelmintic susceptibility status of sheep nematodes in Germany.
- || moxidectin / Generic mfg.
Clinical, Journal: Comparative speed of kill provided by lotilaner (Credelio (Pubmed Central) - Jul 20, 2024
Credelio (lotilaner) has a more rapid onset of acaricidal activity against A. americanum than Simparica Trio (sarolaner-moxidectin-pyrantel) and NexGard (afoxolaner). Only lotilaner's speed of tick kill is sustained throughout the dosing period.
- | moxidectin / Generic mfg.
Journal: Unravelling the Effectiveness of Anthelmintic Treatments on Equine Strongyles on Irish Farms. (Pubmed Central) - Jul 13, 2024
The reduced efficacy of moxidectin was noted on two farms (FECR = 86.90% and 93.50%) and on a third farm with an FECR of 99.50 and a lower HPD interval < 90% at 24.00%. In summary, these findings emphasize the urgent need for alternative strategies in equine strongyle control that reduce reliance on anthelmintics and prioritize effective management practices on Irish equine farms to hinder the impending development of drug-resistant parasite populations.
- || moxidectin / Generic mfg.
Clinical, Journal: Safety and Short-term Efficacy of a Single Dose of 2?mg Moxidectin in Loa loa-Infected Individuals: A Double-Blind, Randomized Ivermectin-Controlled Trial With Ascending Microfilarial Densities. (Pubmed Central) - Jul 5, 2024
P2
Further studies with higher MOX doses and in patients with higher MFD are warranted. NCT04049851.
- | moxidectin / Generic mfg., albendazole / Generic mfg.
Enrollment closed: Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole (clinicaltrials.gov) - Jun 21, 2024
P3, N=12997, Active, not recruiting, Sponsor: Medicines Development for Global Health
NCT04049851. Recruiting --> Active, not recruiting
- | moxidectin / Generic mfg., ivermectin topical / Generic mfg.
Journal: Feline sarcoptic mange in Poland: A case series of three cats. (Pubmed Central) - Jun 12, 2024
The clinical presentation of feline scabies appears to be more variable in cats than in dogs. Infestation with S. scabiei should be considered a differential diagnosis for cats presenting with pruritic inflammatory skin disease.
- | moxidectin / Generic mfg., albendazole / Generic mfg.
Enrollment closed, Head-to-Head: Moxiped: Efficacy and Safety of MOX/ALB Co-administration in SAC (clinicaltrials.gov) - Jun 6, 2024
P3, N=210, Active, not recruiting, Sponsor: Jennifer Keiser
Infestation with S. scabiei should be considered a differential diagnosis for cats presenting with pruritic inflammatory skin disease. Recruiting --> Active, not recruiting
- | moxidectin / Generic mfg., ivermectin oral / Generic mfg., albendazole / Generic mfg.
Enrollment open: Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (clinicaltrials.gov) - Jun 3, 2024
P2, N=300, Enrolling by invitation, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- | moxidectin / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy and Safety Study of Moxidectin in Adults with Scabies (clinicaltrials.gov) - Jun 2, 2024
P2, N=200, Recruiting, Sponsor: Medicines Development for Global Health
Not yet recruiting --> Enrolling by invitation Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- | moxidectin / Generic mfg., albendazole / Generic mfg.
Enrollment open, Head-to-Head: Moxiped: Efficacy and Safety of MOX/ALB Co-administration in SAC (clinicaltrials.gov) - May 22, 2024
P3, N=210, Recruiting, Sponsor: Jennifer Keiser
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 Not yet recruiting --> Recruiting
- | moxidectin / Generic mfg.
Journal: Safety of an oral combination of moxidectin, afoxolaner, and pyrantel pamoate in dogs. (Pubmed Central) - May 17, 2024
Some mild and self-resolving instances of emesis or diarrhea were occasionally observed in the 3X and 5X dosed dogs. NexGard
- | moxidectin / Generic mfg., ivermectin oral / Generic mfg., albendazole / Generic mfg.
Biomarker, Journal: Biomarkers of gastrointestinal nematodes in beef cattle raised in a tropical area. (Pubmed Central) - May 7, 2024
In the second step, pepsinogen was assessed in cattle of the Nelore breed distributed among three groups: infected (not treated with anthelmintic), MOX (treated with moxidectin), and IVM?+?BZD (treated with ivermectin?+?albendazole)...In the second study, a reduction in pepsinogen was found after anthelmintic treatment. Therefore, pepsinogen is a promising biomarker of worms in cattle naturally infected by the genera Haemonchus and Cooperia in tropical areas.
- | moxidectin / Generic mfg.
Journal: An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination. (Pubmed Central) - Apr 25, 2024
Moxidectin-based strategies could accelerate progress toward EoT and reduce programmatic delivery costs compared with ivermectin-based strategies. The costs of moxidectin to national programs are needed to quantify whether delivery cost reductions will translate into overall program cost reduction.
- | monepantel (PAA1) / Pharmaust
Journal: Revisiting anthelmintic resistance in sheep flocks from S (Pubmed Central) - Apr 8, 2024
The costs of moxidectin to national programs are needed to quantify whether delivery cost reductions will translate into overall program cost reduction. In each one of the 15 flocks evaluated, animals (n
- ||| moxidectin / Generic mfg., ivermectin oral / Generic mfg.
P3 data, Journal, Adverse events: Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 (Pubmed Central) - Mar 20, 2024
The impact of SmfD and mfAC levels before and early after treatment on ocular AEs needs to be better understood before making decisions on the risk-benefit of strategies including DEC. Such decisions should take into account interindividual variability in SmfD, mfAC levels and treatment response and risks to even a small percentage of individuals.
- | moxidectin / Generic mfg., levamisole / Generic mfg.
Journal: Efficacy of levamisole, ivermectin and moxidectin against Capillaria spp. in European hedgehogs (Erinaceus europaeus) - CORRIGENDUM. (Pubmed Central) - Mar 15, 2024
Such decisions should take into account interindividual variability in SmfD, mfAC levels and treatment response and risks to even a small percentage of individuals. No abstract available
- | moxidectin / Generic mfg.
Journal: Moxidectin versus ivermectin for strongyloidiasis control. (Pubmed Central) - Feb 26, 2024
No abstract available No abstract available
- | moxidectin / Generic mfg.
Journal: Does Faeces Excreted by Moxidectin-Treated Sheep Impact Coprophagous Insects and the Activity of Soil Microbiota in Subtropical Pastures? (Pubmed Central) - Feb 15, 2024
Thus, the results indicate that faeces excreted from sheep treated with MOX under the experimental conditions of this study are not harmful to the coprophagous insects. However, adding MOX to faeces from drug-free sheep had a negative impact on soil microbial activity and biomass.
- | moxidectin / Generic mfg.
Journal: Evaluation of the efficacy of Simparica Trio in the prevention of the transmission of Babesia canis by infected Dermacentor reticulatus to dogs. (Pubmed Central) - Feb 7, 2024
However, adding MOX to faeces from drug-free sheep had a negative impact on soil microbial activity and biomass. A single treatment with Simparica Trio at the minimum recommended label dose of 1.2
- || moxidectin / Generic mfg.
PK/PD data, Preclinical, Journal: Moxidectin is a candidate for use as an in vivo internal standard in pharmacokinetic studies, as demonstrated with use in simultaneous tissue cage and ultrafiltration fluid collection. (Pubmed Central) - Jan 31, 2024
Moxidectin concentrations in the plasma and tissue cage fluid were stable throughout the 72?h sampling window. Moxidectin proved to be suitable as an in vivo internal standard for pharmacokinetic research using, tissue cages, plasma sampling and ultrafiltration probes, but the application of ultrafiltration techniques requires refinement.
- | moxidectin / Generic mfg.
Journal: Efficacy of a spot-on formulation containing 280 (Pubmed Central) - Jan 29, 2024
The percentage of negative cats was higher in the IVP group compared to the control group and the percentage of reduction of fecal larvae counts in the IVP group compared to the control group was 100%. These results show that two administrations of Bravecto Plus
- | moxidectin / Generic mfg.
Journal: Extraction and analysis of moxidectin in wombat plasma and faeces. (Pubmed Central) - Jan 29, 2024
These results show that two administrations of Bravecto Plus The methods reported here were used to monitor moxidectin in wombats treated with a single pour-on treatment, and confirmed that the moxidectin concentration in wombat plasma had decreased by more than 90
- | moxidectin / Generic mfg.
Journal: Free drug percentage of moxidectin declines with increasing concentrations in the serum of marsupials. (Pubmed Central) - Jan 26, 2024
In addition, wombats showed significantly lower free drug levels. These findings call for further research into the mechanisms of moxidectin protein binding to help understand MOX pharmacokinetics in marsupials.
- | moxidectin / Generic mfg.
Journal: The relationship between Intra-Flagellar Transport and upstream protein trafficking pathways and macrocyclic lactone resistance in Caenorhabditis elegans. (Pubmed Central) - Jan 16, 2024
It has recently been shown in the model nematode Caenorhabditis elegans that the sensory cilia of the amphid neurons play an important role in resistance towards macrocyclic lactones such as ivermectin (an avermectin) and moxidectin (a milbemycin) either through reduced uptake or inter-tissue signalling pathways...In total 24 novel C. elegans anthelmintic survival associated genes were identified in this study. When combined with previously known resistance genes, there are now 46 resistance associated genes which are directly involved in amphid, cilia and IFT function.
- || moxidectin / Generic mfg., praziquantel / Generic mfg.
Clinical, Journal: Prevention of heartworm infection in dogs using a combination of moxidectin, imidacloprid and praziquantel: evidence from a randomized clinical trial. (Pubmed Central) - Jan 11, 2024
Remarkably, the efficacy against the appearance of D. immitis microfilariae was 100% (i.e., all treated dogs negative) and three untreated dogs were positive for microfilariae. The topical combination of moxidectin 3.5%, imidacloprid 10% and praziquantel 10% significantly reduced the risk of D. immitis infection in treated dogs as compared with untreated dogs, in a highly endemic area in north-eastern Brazil.
- | moxidectin / Generic mfg., albendazole / Generic mfg.
New P3 trial, Head-to-Head: Moxiped: Efficacy and Safety of MOX/ALB Co-administration in SAC (clinicaltrials.gov) - Jan 2, 2024
P3, N=210, Not yet recruiting, Sponsor: Jennifer Keiser